UBS Group’s Biomerica BMRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.1K | Sell |
519
-5,293
| -91% | -$12.1K | ﹤0.01% | 9624 |
|
|
2025
Q4 | $14.6K | Buy |
5,812
+5,697
| +4,954% | +$14.8K | ﹤0.01% | 7988 |
|
|
2025
Q3 | $325 | Sell |
115
-434
| -79% | -$1.37K | ﹤0.01% | 9734 |
|
|
2025
Q2 | $1.74K | Sell |
549
-1,487
| -73% | -$5.29K | ﹤0.01% | 9573 |
|
|
2025
Q1 | $9.23K | Sell |
2,036
-871
| -30% | -$4.3K | ﹤0.01% | 8698 |
|
|
2024
Q4 | $6.98K | Sell |
2,907
-8,555
| -75% | -$22.6K | ﹤0.01% | 8514 |
|
|
2024
Q3 | $30.1K | Buy |
+11,462
| New | +$32.8K | ﹤0.01% | 7129 |
|
|
2024
Q2 | – | Sell |
-4,131
| Closed | -$27.5K | – | 9541 |
|
|
2024
Q1 | $27.5K | Buy |
4,131
+3,496
| +551% | +$28.4K | ﹤0.01% | 6772 |
|
|
2023
Q4 | $6.35K | Buy |
635
+346
| +120% | +$2.62K | ﹤0.01% | 7709 |
|
|
2023
Q3 | $1.99K | Buy |
289
+148
| +105% | +$1.47K | ﹤0.01% | 7789 |
|
|
2023
Q2 | $1.53K | Sell |
141
-41
| -23% | -$486 | ﹤0.01% | 7900 |
|
|
2023
Q1 | $2.72K | Sell |
182
-60
| -25% | -$1.29K | ﹤0.01% | 8459 |
|
|
2022
Q4 | $6.47K | Buy |
242
+72
| +42% | +$2.07K | ﹤0.01% | 9030 |
|
|
2022
Q3 | $5K | Buy |
+170
| New | +$4.4K | ﹤0.01% | 9169 |
|
|
2022
Q2 | – | Sell |
-302
| Closed | -$11K | – | 10329 |
|
|
2022
Q1 | $11K | Buy |
302
+128
| +74% | +$4.26K | ﹤0.01% | 8285 |
|
|
2021
Q4 | $5K | Buy |
+174
| New | +$6.7K | ﹤0.01% | 9373 |
|
|
2021
Q3 | – | Sell |
-116
| Closed | -$4K | – | 9547 |
|
|
2021
Q2 | $4K | Buy |
+116
| New | +$3.93K | ﹤0.01% | 8654 |
|
|
2020
Q4 | – | Sell |
-250
| Closed | -$14K | – | 8391 |
|
|
2020
Q3 | $14K | Sell |
250
-63
| -20% | -$4.07K | ﹤0.01% | 6572 |
|
|
2020
Q2 | $18K | Buy |
313
+170
| +119% | +$9.53K | ﹤0.01% | 6613 |
|
|
2020
Q1 | $8K | Buy |
+143
| New | +$4.36K | ﹤0.01% | 7064 |
|
|
2019
Q2 | – | Sell |
-177
| Closed | -$4K | – | 7856 |
|
|
2019
Q1 | $4K | Buy |
+177
| New | +$3.45K | ﹤0.01% | 7246 |
|
|
2018
Q4 | – | Sell |
-287
| Closed | -$8K | – | 8026 |
|
|
2018
Q3 | $8K | Sell |
287
-110
| -28% | -$3.3K | ﹤0.01% | 7264 |
|
|
2018
Q2 | $12K | Buy |
397
+179
| +82% | +$5.43K | ﹤0.01% | 7024 |
|
|
2018
Q1 | $7K | Buy |
+218
| New | +$7.48K | ﹤0.01% | 7065 |
|
|
2017
Q4 | – | Sell |
-27
| Closed | -$1K | – | 7839 |
|
|
2017
Q3 | $1K | Buy |
+27
| New | +$584 | ﹤0.01% | 7559 |
|
|
2017
Q2 | – | Sell |
-38
| Closed | -$1K | – | 7675 |
|
|
2017
Q1 | $1K | Buy |
+38
| New | +$718 | ﹤0.01% | 7404 |
|
Other funds holding BMRA
VCM
VFT
NA
HCM
HI
MA
DB
UBS Group's BMRA Position: Q1 2026 in Review
UBS Group reduced its Biomerica (BMRA) stake by 91% in Q1 2026, selling an estimated $12.1K and leaving 519 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #9624.
UBS Group first reported a position in BMRA in Q1 2017 and has held it in 26 quarters since. The position peaked at $30.1K in Q3 2024. 11 funds tracked by Wall St. Rank hold BMRA as of Q1 2026.
- UBS Group held 519 shares of Biomerica worth $1.1K as of Q1 2026.
- UBS Group sold 5,293 Biomerica shares in Q1 2026, an estimated $12.1K.
- Biomerica made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9624 holding.
- UBS Group first reported a position in Biomerica in Q1 2017 and has held it in 26 quarters since.
- UBS Group's Biomerica position peaked at $30.1K in Q3 2024.
- 11 funds tracked by Wall St. Rank held Biomerica as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.